The IL-6-neutralizing sIL-6R-sgp130 buffer system is disturbed in patients with type 2 diabetes.
Aged
Amino Acid Substitution
Atherosclerosis
/ blood
Case-Control Studies
Cytokine Receptor gp130
/ blood
Diabetes Mellitus, Type 2
/ blood
Female
Hep G2 Cells
Humans
Interleukin-6
/ antagonists & inhibitors
Male
Middle Aged
Phosphorylation
/ drug effects
Polymorphism, Single Nucleotide
Protein Binding
Receptors, Interleukin-6
/ blood
STAT3 Transcription Factor
/ genetics
Signal Transduction
/ drug effects
gp130
interleukin-6
interleukin-6 receptor
type 2 diabetes
Journal
American journal of physiology. Endocrinology and metabolism
ISSN: 1522-1555
Titre abrégé: Am J Physiol Endocrinol Metab
Pays: United States
ID NLM: 100901226
Informations de publication
Date de publication:
01 08 2019
01 08 2019
Historique:
pubmed:
27
6
2019
medline:
19
2
2020
entrez:
26
6
2019
Statut:
ppublish
Résumé
Serum levels of interleukin-6 (IL-6) are increased in patients with type 2 diabetes (T2D). IL-6 exerts its pleiotropic effects via the IL-6 α-receptor (IL-6R), which exists in membrane-bound and soluble (sIL-6R) forms and activates cells via the β-receptor glycoprotein 130 (gp130). The nonsynonymous single-nucleotide polymorphism (SNP) rs2228145 (Asp358Ala) within the
Identifiants
pubmed: 31237452
doi: 10.1152/ajpendo.00166.2019
doi:
Substances chimiques
IL6R protein, human
0
Interleukin-6
0
Receptors, Interleukin-6
0
STAT3 Transcription Factor
0
STAT3 protein, human
0
Cytokine Receptor gp130
133483-10-0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM